Vanda turns back on hostile takeover bid by CDMO Future Pak
Two weeks after gaining a hard-earned FDA label expansion for its long-established antipsychotic drug Fanapt (iloperidone), Vanda Pharmaceuticals has derailed a hostile takeover bid. By employing a shareholder rights plan, commonly known as a “poison pill …